On February 12, 2015, Bloomberg News published an in-depth look at rapamycin, an FDA approved drug that experts now believe may work to delay the onset of the aging process. The article cites seven AFAR affiliated experts: Deputy Scientific Director and three-time Grantee Nir Barzilai, M.D.; two-time Grantee Matt Kaeberlein, Ph.D.; two-time Grantee Brian Kennedy, Ph.D.; 1998 AFAR Award Recipient Valter Longo, Ph.D.; Board Member S. Jay Olshansky, Ph.D.; two-time Grantee Daniel Promislow, Ph.D.; and 2000 AFAR Research Grant Recipient David Sinclair, Ph.D..
Rapamycin has been approved to use against certain kidney, lung, and breast cancers. According the article, there is now evidence that based on animal trials the drug shows promise as a treatment that can not only extend life by delaying the onset of aging-related diseases but also postpone symptoms associated with aging.
Read the full article here.
For more information existing drugs that may be able to extend lifespan, read Dr. Barzilai and Dr. Kennedy’s description of three promising treatments here.
